- Home
- KZR vs NRXP Comparison
KZR vs NRXP Comparison
Compare KZR & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KZR | NRXP |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.3M | 54.2M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | KZR | NRXP |
|---|---|---|
| Price | $6.46 | $1.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $6.00 | ★ $31.50 |
| AVG Volume (30 Days) | 29.3K | ★ 613.8K |
| Earning Date | 03-13-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $847.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.53 | $1.58 |
| 52 Week High | $7.45 | $3.84 |
Technical Indicators
Market Signals| Indicator | KZR | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 48.68 | 45.23 |
| Support Level | $6.63 | $1.66 |
| Resistance Level | $7.35 | $1.99 |
| Average True Range (ATR) | 0.25 | 0.12 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 12.65 | 21.62 |
Price Performance
Historical ComparisonAbout KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.